Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference)-Reference-Cited by-同舟云学术

Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference)

Published:2005-12 Issue:12 Volume:96 Page:85-93
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Kostis John B.,Jackson Graham,Rosen Raymond,Barrett-Connor Elizabeth,Billups Kevin,Burnett Arthur L.,Carson Culley,Cheitlin Melvin,Debusk Robert,Fonseca Vivian,Ganz Peter,Goldstein Irwin,Guay Andre,Hatzichristou Dimitris,Hollander Judd E.,Hutter Adolph,Katz Stuart,Kloner Robert A.,Mittleman Murray,Montorsi Francesco,Montorsi Piero,Nehra Ajay,Sadovsky Richard,Shabsigh Ridwan

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference53 articles.

1. Management of sexual dysfunction in patients with cardiovascular disease;DeBusk;Am J Cardiol,2000

2. Erectile dysfunction and the cardiovascular patient;Solomon;Heart,2003

3. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease;Kaiser;J Am Coll Cardiol,2004

4. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels. A human in vivo study;Gori;Circulation,2005

5. Erectile dysfunction and coronary risk factors;Feldman;Prev Med,2000

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health;The Journal of Sexual Medicine;2023-12-26

2. The impact of heart failure on the sexual response cycle: A systematic review;Heart & Lung;2022-11

3. Identification of phosphodiesterase type-5 (PDE-5) inhibitors in herbal supplements using a tiered approach and associated consumer risk;Food Additives & Contaminants: Part A;2022-03-24

4. Cardiometabolic Diseases and Female Sexual Dysfunction: Animal Studies;The Journal of Sexual Medicine;2022-03-01

5. Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications;The Journal of Clinical Hypertension;2022-01-31